Current trends in the pharmaceutical industry - A case study approach

European Journal of Pharmaceutical Sciences

Volumn 44, Issue 3, 2011, Pages 437-440

  Rusu, Alexandru ^a   Kuokkanen, Katja ^b   Heier, Annabelle ^c,d  

^a Societatea Academica Din Romania   (Romania)

^b ORION CORPORATION   (Finland)

^c ASTRAZENECA   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Corporate social responsibility; Diversification; Generic competition; Open innovation; Pipeline management

Indexed keywords

ATORVASTATIN; FOOT AND MOUTH DISEASE VACCINE; GENERIC DRUG; MONOCLONAL ANTIBODY; NON PRESCRIPTION DRUG; NUTRACEUTICAL; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RNA;

CAPITAL; CASE STUDY; COMPETITION; CORPORATE SOCIAL RESPONSIBILITY; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; ENVIRONMENTAL FACTOR; FOOT AND MOUTH DISEASE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; LICENSING; NONHUMAN; PIPELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROFIT; REVIEW; SOCIAL BEHAVIOR; TAX; TREND STUDY; VETERINARY MEDICINE;

EID: 80053910795     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.07.008     Document Type: Note

References (23)

1. Access to Medicines Index, 2010. < http://www.accesstomedicineindex. org/ > (accessed 11.06.11).
2. Anscombe, J., Wise, M., Cruickshank, C., Hanfland, D., Thomas, M., Sawaya, O., 2009. Pharmaceuticals Out of Balance. Reaching the tipping point. A. T. Kearney. September. < http://www.atkearney.com/index.php/Publications/ pharmaceuticals-out-of-balance.html > (accessed 11.06.11).
3. D. Crommelin, P. Stolk, L. Besancon, V. Shah, K. Midha, and H. Leufkens Pharmaceutical sciences in 2020 Nat. Rev. Drug. Discovery 9 2010 99 100
4. Danner, S., Hosseini, M., Rimpler, M., 2010. Fight or Fligh. Diversification vs. Rx focus in Big Pharmás quest for sustained growth. Roland Berger Strategy Consultants. October. < http://www.rolandberger.com/ expertise/industries/pharmaceuticals/2010-10-25-rbsc-pub-Fight-or-flight.html > (accessed 11.06.11).
5. IMS Health, Succeeding in Pharmerging Markets. < http://www.imshealth. com/portal/site/imshealth/menuitem.a953aef4d73d1ecd88f611019418c22a/?vgnextoid= 7579f96f7be65210VgnVCM100000ed152ca2RCRD > (accessed 11.06.11).
6. PricewaterhouseCoopers, 2009a. Pharma 2020: Challenging business models. April. < http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020-business- models > (accessed 11.06.11).
7. PricewaterhouseCoopers, 2009b. Pharma 2020: Taxing times ahead. December. < http://www.pwc.com/gx/en/pharma-life-sciences/pharma-2020/pharma-2020- taxing-times-ahead.jhtml >. (accessed 11.06.11)
8. Winslow, R., 2000, "Birth of a Blockbuster: Lipitor's Unlikely Route Out of the Lab," The Wall Street Journal, January 24, B1. Available from < http://www.oralchelation.net/data/Cholesterol/data11d.htm (accessed 11.06.11).
9. World Pharma News, 2009. Pfizer in Partnership with Shanghai Institutes for Biological Sciences for Drug Discovery Activities. July 30. < http://www.worldpharmanews.com/pfizer/875-pfizer-in-partnership-with-shanghai- institutes-for-biological-sciences-for-drug-discovery-activities > (accessed 11.06.11).
10. Crucell, 2004. Press release, October 18 "Crucell and Merial Announce Commercial License Agreement for PER.C6® Technology for Foot-and-Mouth Disease Vaccines". < http://hugin.info/132631/R/964410/ 139709.pdf (accessed 11.06.11).
11. Crucell, 2010. Annual Report 2009. < http://crucell.com/annual-report- 2009/pdfs/Crucell-AR09-Complete.pdf >. (accessed 11.06.11)
12. Crucell, 2011. Press release. February 7. < http://hugin.info/132631/ R/1485773/420938.pdf > (accessed 11.06.11).
13. Johnson & Johnson, 2011. Press release, March 8, "Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs". < http://www.investor.jnj.com/releasedetail.cfm?releaseid=555562 > (accessed 11.06.11).
14. Merck, 2010, Form 10-K 2009. < http://www.merck.com/investors/ financials/form-10-K-2009-final.pdf > (accessed 11.06.11.
15. Merck, 2011. Form 10-K 2010. < http://www.merck.com/investors/ financials/form-10-k-2011.pdf > (accessed 11.06.11).
16. Novo Nordisk, 2011a. Annual Report 2010. < http://annualreport2010. novonordisk.com/web-media/pdfs/Novo-Nordisk-AR-2010-en.pdf > (accessed 11.06.11).
17. Novo Nordisk website, 2011b. Changing Diabetes Programmes. < http://www.novonordisk.com/about-us/changing-diabetes/cd-programmes.asp > (accessed 11.06.11).
18. Pfizer, 2010. Form 10-K 2009. < www.pfizer.com/files/annualreport/ 2009/form10k-2009.pdf > (accessed 11.06.11).
19. Pfizer, 2011a. 2010 Financial Report. < http://www.pfizer.com/files/ annualreport/2010/financial/financial2010.pdf > (accessed 11.06.11).
20. Pfizer, 2011b. Form 10-K 2010. < http://www.pfizer.com/files/ annualreport/2010/form10k-2010.pdf > (accessed 11.06.11).
21. Pfizer website, 2011c. "Pfizer Pipeline. As of February 28, 2011". < http://www.pfizer.com/files/research/pipeline/2011-0228/ pipeline-2011-0228.pdf > (accessed 11.06.11).
22. ResPig website. http://www.respig.com/ > (accessed 11.06.11).
23. ViiV Healthcare website, 2011. At a glance. < http://www. viivhealthcare.com/about-us/at-a-glance.aspx > (accessed 11.06.11).